Immunovant Inc.
IMVTHeld by 12 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying12 funds opened new positions. Next phase3 readout (Batoclimab 680 mg SC weekly): Jan 2025. Short interest: 20.9% of float.
Held by 12 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying12 funds opened new positions. Next phase3 readout (Batoclimab 680 mg SC weekly): Jan 2025. Short interest: 20.9% of float.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.